- Successful Primary Infliximab Treatment of Orofacial Crohn's Disease without Gastrointestinal Manifestation
-
Jung BY, Lee SH, Chung SK, Lee CK, Lee TH, Chung IK, Kim SJ, Cho HD
- KMID: 1792850
- Korean J Gastroenterol.
- 2012 Jun;59(6):437-440.
- doi: 10.4166/kjg.2012.59.6.437
Crohn's disease is a chronic inflammatory bowel disease that can involve the whole gastrointestinal tract. The orofacial manifestation of Crohn's disease, which is rare, can develop irrespective of intestinal involvement.... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Crohn's Disease Showing Favorable Response to Induction and Maintenance Therapy with Methotrexate after Failure of Anti-tumor Necrosis Factor Therapy
-
Choi J, Yun GW, Park YM, Kim JH, Youn YH, Park H, Park JJ
- KMID: 2373347
- Korean J Gastroenterol.
- 2015 Oct;66(4):231-236.
- doi: 10.4166/kjg.2015.66.4.231
Thanks to the introduction of immumomodulators and biologics, therapeutic approaches in Crohn's disease have changed significantly during the past decade. Although new biologic therapy has dramatically improved the treatment of... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Psoriasis Induced by Infliximab Treatment for Crohn's Disease
-
Jwa YJ, Kim NH, Park HJ, Park JS, Bae WK, Kim KA, Lee JS, Moon YS
- KMID: 1718375
- Korean J Gastroenterol.
- 2010 Nov;56(5):324-328.
- doi: 10.4166/kjg.2010.56.5.324
Infliximab, the monoclonal antibody to tumor necrosis factor, is indicated for refractory luminal and fistulizing Crohn's disease and rheumatoid arthritis. Infliximab treatment has adverse events including infusion reactions, opportunistic infections,... -
- CITED
-
- Close
- SHARE
-
- Close
